145 related articles for article (PubMed ID: 37553731)
1. Combination therapy may create a practice change for advanced or recurrent endometrial cancer: Two new studies show the value of adding immunotherapy to standardof-care chemotherapy to improve progression-free survival.
Nierengarten MB
Cancer; 2023 Sep; 129(17):2600-2601. PubMed ID: 37553731
[No Abstract] [Full Text] [Related]
2. ICI-Chemo New Standard for Endometrial Cancer.
Cancer Discov; 2023 May; 13(5):1030-1031. PubMed ID: 36988284
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Vale CL; Tierney J; Bull SJ; Symonds PR
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD003915. PubMed ID: 22895938
[TBL] [Abstract][Full Text] [Related]
4. Management of advanced-stage and recurrent endometrial cancer.
Ray M; Fleming G
Semin Oncol; 2009 Apr; 36(2):145-54. PubMed ID: 19332249
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
6. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer?
Herzog TJ
Gynecol Oncol; 2004 Jan; 92(1):1-3. PubMed ID: 14751129
[No Abstract] [Full Text] [Related]
7. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy in metastatic or recurrent endometrial cancer.
Pectasides D; Pectasides E; Economopoulos T
Cancer Treat Rev; 2007 Apr; 33(2):177-90. PubMed ID: 17196749
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
Humber CE; Tierney JF; Symonds RP; Collingwood M; Kirwan J; Williams C; Green JA
Ann Oncol; 2007 Mar; 18(3):409-20. PubMed ID: 17150999
[TBL] [Abstract][Full Text] [Related]
10. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Humber C; Tierney J; Symonds P; Collingwood M; Kirwan J; Williams C; Green J
Cochrane Database Syst Rev; 2005 Oct; (4):CD003915. PubMed ID: 16235346
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Humber C; Tierney J; Symonds P; Collingwood M; Kirwan J; Williams C; Green J
Cochrane Database Syst Rev; 2005 Jul; (3):CD003915. PubMed ID: 16034916
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA
Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of endometrial cancer revisited].
Fehr MK; Wight E; Haller U
Gynakol Geburtshilfliche Rundsch; 1999; 39(3):110-20. PubMed ID: 10420053
[TBL] [Abstract][Full Text] [Related]
16. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
20. [The validity of chemotherapy in the treatment of endometrial cancer].
Fehr MK; Streich MS
Gynakol Geburtshilfliche Rundsch; 2006; 46(1-2):34-8. PubMed ID: 16452818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
